Smurph,

Thanks. Very informative summary of the background of the RO issue.

Which brings me to LH's.

All the evidence points to a very complex condition which will require a complex solution.

We have a big disadvantage: we don't have a research team that can put us in the "right" path. Quick.

We have a big advantage: we have a very good drug that, potentially, can play a key role in solving the puzzle.

The problem is, we need to know what the puzzle will look like when all the pieces are assembled.

And, we don't.

Doing "exploratory" short trials, to find answers, the way we are doing, might be a good approach.

With a problem: there are companies with labs and 10's of scientists working on this measuring, trying, measuring again .... They will assemble the puzzle before us as this condition is one of first figuring it out and then solving it.

We need to seek for partners, both in complementary drug(s) and in research capabilities.

We are not a COVID company, but the exposure and approval of Leronlimab will bring us great collateral benefit: recognition.

The other BIG prizes we can go solo.

But no LH COVID, imho.

Looking forward to CC mainly to learn what is happening in the Oncology front.

We will be the next Keytruda++ but need to strengthen first to fight that fight ...